Compare WNEB & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | IPHA |
|---|---|---|
| Founded | 1853 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 141.7M |
| IPO Year | 2001 | N/A |
| Metric | WNEB | IPHA |
|---|---|---|
| Price | $13.86 | $1.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.50 | $5.75 |
| AVG Volume (30 Days) | ★ 48.7K | 23.6K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $18.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.53 | $1.18 |
| 52 Week High | $14.52 | $2.63 |
| Indicator | WNEB | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 46.46 |
| Support Level | $12.07 | $1.18 |
| Resistance Level | $14.06 | $1.80 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 69.07 | 23.26 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.